Anyone who invests in German biotechnology must have patience, money and skill - and sufficient luck.
Says someone who should know, because Michael Motschmann, founder of the MIG funds, is not only an important venture capital investor in Germany, but above all, together with his board colleague Matthias Kromayer, the one who realizes the potential of the founding couple Ugur Sahin and Özlem Türeci discovered early on.
Since then, he has promoted them together with the Hexal founders Thomas and Andreas Strüngmann. Motschmann's investment company MIG is one of the founding investors of Biontech;
As a member of the Supervisory Board, he accompanied the dramatic search for the vaccine against the pandemic from the start.
In an interview with WELT, he explains what has to happen so that the next biontechs can mature in Germany.